Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
about
Trial watch: Immune checkpoint blockers for cancer therapy.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.The role of nivolumab in melanoma.Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.Impact of genomics on the surgical management of melanoma.Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.Pushing the limits of immune-related response: a case of "extreme pseudoprogression".An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.Do immune checkpoint inhibitors need new studies methodology?Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialNivolumab-induced systemic vasculitisImmune Checkpoint Inhibition in Head and Neck Cancer
P2860
Q47393365-84CB71E7-4C23-4922-BF6D-82DF6EB4CEB5Q47718879-F584D790-B493-4D53-9CAF-37DF5C704C8CQ47735641-B4D39F82-B845-470C-8CA9-BDFEC7716086Q49821320-D18DFBE0-B6D2-4D97-91A0-0631C84284E0Q50010320-8C6FE05A-57C7-47FB-A1F2-2DD1509CFC79Q50089384-0A6E5767-5ECE-498F-BF38-DE1F4F3B6AA4Q54112267-27963FFF-021B-4EFD-A47B-E3611E915436Q55206910-59749C95-8418-4F3E-9AE1-BD0445BDEF1CQ55235148-2350804D-AA20-44B1-AAAB-06740E32B856Q55375458-596F8F93-C15C-4B04-963B-5C0EA8A882FAQ56383260-E7DA1E99-2CE8-409D-859E-8BBD2990DB87Q56891658-00EB0C7B-B652-4317-A389-985C729449B3Q58694216-B35BCC6B-DC1C-4529-BD27-FE863D74CDAD
P2860
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Nivolumab for Patients With Ad ...... of 2 Phase 3 Clinical Trials.
@en
type
label
Nivolumab for Patients With Ad ...... of 2 Phase 3 Clinical Trials.
@en
prefLabel
Nivolumab for Patients With Ad ...... of 2 Phase 3 Clinical Trials.
@en
P2093
P2860
P50
P1433
P1476
Nivolumab for Patients With Ad ...... of 2 Phase 3 Clinical Trials.
@en
P2093
Catriona McNeil
F Stephen Hodi
Georgina V Long
Henrik Schmidt
Ivan Márquez-Rodas
James Larkin
Jean-François Baurain
Jean-Jacques Grob
Jedd D Wolchok
Jeffrey S Weber
P2860
P356
10.1001/JAMAONCOL.2017.1588
P577
2017-06-29T00:00:00Z